Publication | Open Access
Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States
20
Citations
32
References
2023
Year
VaccinationPreterm Infants 29–34Respiratory Virus ImmunityNeonatologyPediatricsPediatric Lung DiseasePreterm BirthNewborn MedicinePreterm Birth PreventionMedicineUnited States
| Year | Citations | |
|---|---|---|
Page 1
Page 1